Wedbush Maintains Outperform on Beam Therapeutics, Raises Price Target to $30
Benzinga Newsdesk 2 days ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.
Wedbush analyst David Nierengarten maintains Beam Therapeutics (NASDAQ:BEAM) with a Outperform and raises the price target from $28 to $30.